The deal, which values Antares at roughly $960 million, deepens Halozyme’s focus on drug delivery.
The deal, which values Antares at roughly $960 million, deepens Halozyme’s focus on drug delivery.
Source: Read More
PAID
The deal, which values Antares at roughly $960 million, deepens Halozyme’s focus on drug delivery.
The deal, which values Antares at roughly $960 million, deepens Halozyme’s focus on drug delivery.
Source: Read More
PAID